Could a new sedative keep seniors Clear-Headed after cancer surgery?

NCT ID NCT07351474

Not yet recruiting Symptom relief Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether remimazolam, a newer anesthetic, can reduce the risk of postoperative delirium (sudden confusion) in elderly patients undergoing laparoscopic stomach cancer surgery. Researchers will compare remimazolam to standard anesthesia in 170 patients aged 65 and older. The goal is to see if this drug leads to better recovery and fewer cognitive issues after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Remimazolam
What this could lead to: If successful, this could point toward a safer anesthetic option for elderly patients, potentially reducing confusion and cognitive decline after major surgery.
What could go wrong: This is a small, early-stage trial (170 participants) that has not yet started recruiting. The results may not apply to all patients, and remimazolam may not prove better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Emergence Delirium gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER POSTOPERATIVE DELIRIUM

Contacts and locations

Locations

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.